Study backs glargine safety

While the trial failed to demonstrate what it set out to show – that glargine would reduce risk of cardiovascular events compared to standard care – Australian investigator Associate Professor Michael D’Emden said the outcomes provided reassurance of insulin safety, including no increased cancer risk.

The study of 12,500 patients including 150 Australians, found patients using glargine were able to maintain near-normal fasting plasma glucose and glycated haemoglobin levels for up to seven years.

The trial was also investigating whether 1g/day